Omar Zmeili is an Endocrinology/Metabolic physician affiliated with Summa Health System. OpenAlex indexes 7 publications with 299 citations (h-index 2).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
75 Arch St
301
Akron, OH 443041429
Telephone
330-253-1899Registry record last updated 23 Jul 2013.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20251 payment
- Insulet CorporationProgram year20251 payment
- Xeris Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.3%GLP-1 receptor agonist17.7%Trulicity50%Ozempic43%Mounjaro4%Rybelsus3%Part D<11 patientsInsulin Analog15.8%Lantus Solostar28%Insulin Lispro Kwikpen U-10013%Humalog Kwikpen U-1009%Toujeo Solostar9%Tresiba Flextouch U-2006%Humalog6%Novolog Flexpen5%Tresiba Flextouch U-1005%Toujeo Max Solostar5%Basaglar Kwikpen U-1004%Insulin Lispro4%Novolog3%Semglee (Yfgn) Pen3%Humalog Kwikpen U-2002%Part D<11 patients+ 6 more classes in this area
Hormonal (systemic)
22.2%l-Thyroxine17.2%Levothyroxine Sodium92%Synthroid9%Part D≥145 patientsThyroid Hormone Synthesis Inhibitor3.9%Methimazole100%Part D≥34 patients+ 2 more classes in this area
Cardiovascular
16.9%Statin9.2%Atorvastatin Calcium74%Rosuvastatin Calcium20%Pravastatin Sodium6%Part D<11 patientsOther lipid modifying agents3.3%Vascepa72%Icosapent Ethyl28%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sixth-nerve palsy in a patient with uncontrolled type 1 diabetes
Journal of Clinical and Translational Endocrinology Case Reports
2024 - SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
Journal of the Endocrine Society
2020 - SAT-481 Pembrolizumab-Induced Thyroiditis with Negative Thyroid Peroxidase Antibody
Journal of the Endocrine Society
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas File, MD
Summa Health System
Marc Penn, MD
Summa Health System
Drazen Petrinec, MD
Summa Health System
Sameer Mahesh, MD
Summa Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”